Clinical Trial Update: Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

A Phase 2 trial compared the efficacy and tolerability of T1210 to olopatadine hydrochloride 0.1% for seasonal allergic conjunctivitis and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Conjunctivitis

Drugs mentioned

• Olopatadine Hydrochloride 0.1% (olopatadine hydrochloride)
• T1210

Snippet

Sponsor: Laboratoires Thea | Conditions: Seasonal Allergic Conjunctivitis | Phase 2 | Status: COMPLETED